Clinical Trials Logo

Sarcoma, Kaposi clinical trials

View clinical trials related to Sarcoma, Kaposi.

Filter by:

NCT ID: NCT00002439 Completed - HIV Infections Clinical Trials

A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .

NCT ID: NCT00002366 Completed - HIV Infections Clinical Trials

The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.

NCT ID: NCT00002342 Completed - HIV Infections Clinical Trials

A Study of Tecogalan Sodium

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

NCT ID: NCT00002319 Completed - HIV Infections Clinical Trials

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in controlled studies of limited duration, or those with KS who discontinued treatment with another Kaposi's sarcoma therapy because of inadequate efficacy or unacceptable toxicity. To provide a defined protocol for Kaposi's sarcoma patients for whom DOX-SL therapy is indicated.

NCT ID: NCT00002314 Completed - HIV Infections Clinical Trials

A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.

NCT ID: NCT00002262 Completed - HIV Infections Clinical Trials

A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF injections on Kaposi's sarcoma (KS) lesions as measured by P-32 magnetic resonance spectroscopy.

NCT ID: NCT00002259 Completed - HIV Infections Clinical Trials

Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.

NCT ID: NCT00002226 Completed - HIV Infections Clinical Trials

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.

NCT ID: NCT00002212 Completed - HIV Infections Clinical Trials

A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if it is safe and effective to give Targretin capsules to patients with AIDS-related Kaposi's sarcoma (KS).

NCT ID: NCT00002189 Completed - HIV Infections Clinical Trials

Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

Start date: n/a
Phase: Phase 2
Study type: Interventional

To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour infusion of paclitaxel every 14 days. To evaluate the clinical benefit of paclitaxel in this patient population by evaluating self-reported responses to the Symptom Distress Scale and by documenting and evaluating any changes in their lymphedema, pain and disfiguring facial lesions.